Texas statewide hepatitis C counseling and testing, 2000-2005

Public Health Reports

Volumn 122, Issue SUPPL. 2, 2007, Pages 6-11

  Heseltine, Gary ^a   McFarlane, Jenny ^a  

^a TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

COUNSELING; FUNDING; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MEDICAL EDUCATION; MEDICOLEGAL ASPECT; PATIENT REFERRAL; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SUBSTANCE ABUSE; UNITED STATES; ARTICLE; EPIDEMIOLOGY; HEALTH EDUCATION; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PUBLIC HEALTH SERVICE;

COUNSELING; HEALTH EDUCATION; HEPATITIS C; HUMANS; PATIENT EDUCATION; PUBLIC HEALTH PRACTICE; REFERRAL AND CONSULTATION; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; TEXAS;

EID: 34250344132     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/00333549071220s202     Document Type: Review

References (13)

1. Centers for Disease Control and Prevention (US). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998;47(RR-19):1-39.
2. Texas Department of Health. Hepatitis C: an emerging health concern for Texans. White paper. Austin (TX): Texas Department of Health, 1999.
3. Stevens F, Dudley T, Freeman A. Hepatitis C initiative: a qualitative look at integration with HIV/STD program activities. Dallas (TX): University of Texas Southwestern Medical Center; 2004 Sep 1.
4. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep 2003;52(RR-3):1-13,15.
5. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA 1998;280:11 1-7.
6. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C infection in the United States, 1999 through 2002. Ann Intern Med 200 ;144:705-14.
7. Melville SK, Heseltine G, Delamater E, Gilani Z, Hendricks K, Suarez L. Hepatitis C virus seroprevalence: selected health care settings in Texas. Tex Med 200 ;102:5-1.
8. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998;51:253-3.
9. Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS. Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis 2001;28:1-70.
10. Stringari-Murray S, Clayton A, Chang J. A model for integrating hepatitis C services into an HIV/AIDS program. J Assoc Nurses AIDS Care 2003;14(5 Suppl):95S-107S.
11. Strauss SM, Astone JM, Des Jarlais DC, Hagan H. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. AIDS Patient Care STDS 2005;19:78-88.
12. Macalino GE, Dhawan D, Rich JD. A missed opportunity: hepatitis C screening of prisoners. Am J Public Health 2005;95:1739-40.
13. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS 2005;19(Suppl 3):S41-S4.